Cadila Healthcare has posted satisfactory performance during the fourth quarter ended March 2016 and its consolidated net profit increased by 11.1 per cent to Rs.389 crore from Rs.350 crore in the corresponding period of last year. EBDITA improved by 17.3 per cent to Rs.606 crore from Rs.516 crore. Its net sales increased by 5.7 per cent to Rs.2,376 crore from Rs.2,247 crore. EPS worked out to Rs.3.80 as against Rs.3.42 in the last period.

For the full year ended March 2016, Cadila's consolidated net sales increased by 11.4 per cent to Rs.9,469 crore from Rs.8,497 crore in the previous year. Its net profit has taken jump of 32.2 per cent and touched to Rs.1,523 crore from Rs.1,151 crore. Its EPS moved up to Rs.14.87 from Rs.11.24 in the previous year.

The formulations business in the US was the largest contributor to the consolidated revenues and the key driver of the overall growth. Its formulations business in US grew by 19 per cent and crossed $600 million mark in sales for the first time. The company filed 30 ANDAs with the US FDA, taking the cumulative filings to 269. It received approval for 10 ANDAs taking the total to 103 product approvals.

Its formulation business in India improved by 11 per cent on the back of launch of more than 40 new products, including line extensions. Similarly, its business in emerging markets went up by 17 per cent.

Meanwhile, the company has appointed Apurva S Diwanji as an additional independent director of the company for a period of five years from May 13, 2016.